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Summary 
Schistosoma mansoni is a blood fluke parasite responsible for schistosomiasis. The best long-term 
strategy to control schistosomiasis is through immunization combined with drug treatment. In this 
study, we cloned, expressed and purified SmTSP-2 fused to the N- and C-terminal halves of Sm29 
and tested these chimeras as vaccine candidates using an adjuvant approved to be used in humans. 
The results demonstrated that vaccination with SmTSP-2 fused to N- or C- terminus of Sm29 induced 
reduction in worm burden and liver pathology when compared to control animals. Additionally, we 
detected high levels of mouse specific IgG, IgG1 and IgG2a against both chimeras and significant 
amounts of IFN-γ and TNF-α and no IL-4. Finally, studies with sera from patients resistant to infection 
and living in schistosomiasis endemic areas revealed high levels of specific IgG to both chimeras 
when compare to healthy individuals. In conclusion, SmTSP-2/Sm29 chimeras tested here induced 
partial protection against infection and might be a potential vaccine candidate. 
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1. Introduction 
Schistosomiasis is one of the most important chronic parasitic diseases (1). Currently, it is estimated 
207 million people are infected with schistosomes distributed throughout 76 countries (2-3). The 
major intervention used to control the disease is treatment with the anthelmintic drug praziquantel, 
accompanied by the provision of safe water, adequate sanitation and, where possible, control of the 
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snail intermediate host (1-2, 4-5). Nevertheless, the current schistosomiasis control programs have 
particular limitations, particularly the fact that mass treatment does not prevent reinfection. The 
development of drug resistance by the parasite is also a concern that has to be considered (6). 
Likewise long-term effective disease control will benefit from the combination of vaccination and 
chemotherapy, plus sanitation and public health control measures (6).  
 
Vaccination against schistosomes can be targeted towards the prevention of infection and/or the 
reduction of parasite fecundity. A reduction in worm numbers is the “gold standard” for anti-
schistosome vaccine development (7). Therefore, using this “gold standard” methodology some of 
the most promising S. mansoni vaccine antigens discovered in the last years are the tegument 
proteins SmTSP-2 (8-9) and Sm29 (10) . Vaccination of mice with the recombinant protein SmTSP-2 
formulated in Freund’s adjuvant followed by challenge infection with S. mansoni resulted in 
reductions of 57%, 64% and 65-69% for adult worm burdens, liver egg burdens and fecal egg counts, 
respectively (9). Additionally, vaccination with the recombinant Sm29 also formulated with Freund’s 
adjuvant provided 51%, 60% and 50% reduction in adult worm burdens, intestinal eggs and in liver 
granuloma numbers, respectively (10). Therefore, we combined these two molecules in a chimeric 
recombinant form to increase Sm29 solubility due to TSP-2 properties and to enhance protection 
efficacy induced by single antigen vaccination.  
 
An interesting strategy to induce higher protection is the use of multivalent vaccines. Such a strategy 
is normally used in DNA vaccine studies, and induces higher protective efficacy than when the 
antigen is tested alone (11-13). In an attempt of test a multivalent vaccine against schistosomiasis 
formulated with CpG- alum as adjuvant, we evaluated the protective effect of a SmTSP-2/Sm29 
recombinant protein chimera in mice. Two recombinant proteins termed chimera A which present 
two predicted epitopes of Sm29 (SmTSP-2 plus the N-terminus of Sm29) and chimera B which 
present tree predicted epitopes of Sm29 (SmTSP-2 plus the C-terminus of Sm29) were produced and 
tested as potential candidate vaccines against S. mansoni infection. The epitopes were predicted 
using the computer program BCPREDS (14). Mice immunized with both chimeras plus CpG-Alum 
adjuvant had reduced worm burden and liver pathology after challenge infection with S. mansoni. 
Furthermore, sera from patients living in schistosomiasis endemic areas strongly recognized both 
recombinant chimeras A and B.  
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2. Materials and methods 
2.1.Mice and parasites 
Female C57BL/6 mice aged 6–8 weeks were purchased from the Federal University of Minas Gerais 
(UFMG) animal facility. Cercariae of S. mansoni (LE strain) were maintained routinely in 
Biomphalaria glabrata snails at CPqRR (Centro de Pesquisa René Rachou-Fiocruz) and prepared by 
exposing infected snails to light for 1 h to induce shedding. Cercarial numbers and viability were 
determined using a light microscope prior to infection. All protocols were approved by the 
Committee for Ethics in Animal Experimentation (CETEA) at Universidade Federal de Minas Gerais 
UFMG under permit 179/2010. 
 
2.2.Cloning of the S. mansoni SmTSP-2/Sm29 cDNA 
The chimeras SmTSP-2/Sm29A and SmTSP-2/Sm29B were cloned into a modified pET41a vector, 
within the N-terminal GST fusion protein replaced by SmTSP-2 EC-2 into the NdeI and KpnI 
restriction sites. The polymerase chain reaction (PCR) fragments corresponding to Sm29A (N-
terminal Val27-Leu87) or Sm29B (C-terminal Cys88-Lys169) were cloned into the NcoI and XhoI sites 
of the modified pET41a plasmid generating the chimera A and chimera B, respectively. These 
constructs were transformed into Escherichia coli Rosetta-gamiTM electrocompetent cells using the 
gene Pulser SystemTM (Bio-Rad). E. coli transformants harboring the plasmids were screened on LB 
agar plates containing kanamycin (50 μg/ml), chloramphenicol (34 μg/ml) and tetracycline (12.5 
μg/ml). DNA sequencing was performed to confirm the presence and the correct orientation of the 
chimeras' open reading frames.  
 
2.3.Expression and purification of the recombinant chimera A and B 
Chimeras A and B were expressed in E. coli with an in-frame 6x-histidine C-terminal tag using the 
pET41a expression vector. An E. coli Rosetta-gami (DE3) culture containing the recombinant plasmid 
was grown at 30 oC to an optical density of approximately 0.5-0.8 at 600nm and gene expression of 
both chimeras was induced using 1 mM IPTG. After 16 hours of induction, the bacterial cells were 
harvested by centrifugation at 4,000 g for 20 min. The pellet was resuspended in 50 ml of 10 mM 
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Na2HPO4, 10 mM NaH2PO4, 0.5 M NaCl and 10 mM imidazole. Subsequently, the cells were 
submitted to three cycles of sonication lasting 30 s each and centrifuged at 5400 g for 20 min. The 
chimeras A and B were recovered as inclusion bodies and solubilized in 50 ml of 8 M urea, 10 mM 
Na2HPO4, 10 mM NaH2PO4, 0.5 M NaCl, and 10 mM imidazole. The proteins were purified by affinity 
chromatography on a Ni-Sepharose column (Hitrap chelating 5 mL) under denaturing conditions 
using an AKTAprime Plus chromatography system (GE Healthcare, São Paulo, Brazil) according to the 
manufacturer’s protocol. Fractions containing the chimeras A and B were dialyzed against PBS pH 
7.0. The dialysis was carried out at 4 oC using a Spectra/Por2 membrane (MWCO 6 to 8 kDa; 
Spectrum Medical Industries, Inc., Laguna Hills, CA). These recombinant proteins were quantified 
using the Bradford’s method (Coomassie Protein Assay Kit, Pierce) and used as antigen for 
vaccination and immunological experiments. 
 
2.4. SDS-PAGE and immunoblotting 
SDS-PAGE of purified chimeras A and B were performed (15) and the gel electroblotted onto 
nitrocellulose membrane (16). The membrane was then blocked with TBST (0·5 M NaCl−0·02 M Tris 
(pH 7·5), 0·05% Tween 20) containing 5% non-fat dry milk for 16 hrs at room temperature. 
Subsequently, the membrane was incubated in a 1:2000 dilution of anti-6xHIS antibodies (GE 
Healthcare) in TBST for 1 hr at room temperature. After three washes using TBST, the membrane 
was incubated in 1:2000 mouse IgG conjugated with alkaline phosphatase (AP) and treated with AP 
reaction developing buffer containing nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-1-
phosphate (BCIP). After the reaction was developed, the membrane was washed using distilled 
water and dried on filter paper.  
 
2.5. Mice Immunization 
Six to eight week-old female C57BL/6 mice were divided into four groups of ten mice each. Mice 
were subcutaneously injected in the nape of the neck with 100 μl containing 25 μg of chimera A, 
chimera B, Sm29 alone or PBS plus adjuvant as a control group at days 0, 15 and 30 as previously 
reported by our group (10, 17). The recombinant protein and the control group was formulated with 
20 μg of CpG (10104)-Alum (Sigma) as adjuvant. 
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2.6. Challenge infection and worm burden recovery 
Fifteen days after the last boost, mice were challenged through percutaneous exposure of 
abdominal skin for 1 h in water containing 100 cercariae (LE strain). Forty-five days after challenge, 
adult worms were perfused from the portal veins (18). Two independent experiments were 
performed to determine protection levels. The protection was calculated by comparing the number 
of worms recovered from each vaccinated group with its respective control group, using the 
formula: 
 
PL = WRCG – WREG x 100/ WRCG  
Where PL = protection level, WRCG = worms recovered from control group, and WREG = worms 
recovered from experimental group. 
 
2.7.Measurement of specific antibodies 
Following immunization, sera of ten mice from each vaccinated or control group were collected at 
two-week interval. Measurements of specific antibodies IgG, IgG1 and IgG2a to each immunized 
group were performed using indirect ELISA. Maxisorp 96-well microtiter plates (Nunc, Denmark) 
were coated with 5 µg/ml of each protein (chimera A, chimera B and Sm29) in carbonate-
bicarbonate buffer, pH 9.6 for 16 hrs at 4 oC, then blocked for 2 hrs at room temperature with 200 
µl/well PBST (phosphate buffer saline, pH 7.2 with 0.05% Tween-20) plus 10% FBS (fetal bovine 
sera). One hundred microliters of each serum from the chimera A, chimera B and Sm29  immunized 
group was diluted 1:100 in PBST  and  added per well in plates previously sensitized with the 
proteins chimera A, chimera B and Sm29, respectively.  
 
Plate-bound antibody was detected by peroxidase-conjugated anti-mouse IgG, IgG1 and IgG2a 
(Sigma) diluted in PBST 1:10000, 1:5000 and 1:2000, respectively. Antigen concentration and the 
dilutions of mouse serum and secondary antibodies were optimized as previously described (17-18) 
.Color reaction was developed by addition of 100 µl per well of 200 pmol OPD (o-phenylenediamine, 
Sigma) in citrate buffer, pH 5.0 plus 0.04% H2O2 for 10 min and stopped with 50 µl of 5% sulfuric acid 
per well. The plates were read at 495 nm in an ELISA plate reader (BioRad, Hercules, CA). 
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2.8. Cytokine analysis 
Cytokine experiments were performed using splenocyte cultures from individual mice immunized 
with chimera A, chimera B, or PBS plus CpG-Alum as control (n=4 for each group). Splenocytes were 
isolated from macerated spleens of individual mice one week after the third immunization and 
washed twice with sterile PBS as previously described (17-18) . After washing, the cells were 
adjusted to 1x106 cells per well for IL-4, IFN-γ and TNF-α assays in RPMI 1640 medium (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% FBS, 100 U/ml of penicillin G sodium, 100 µg/ml of 
streptomycin sulfate, 250 ng/ml of amphotericin B. Splenocytes were maintained in culture with 
medium alone or stimulated with the recombinant proteins  chimera A and B (25 µg/ml) or with 
concanavalin A (ConA) (5 μg/mL) for IL-4 and IFN-γ, and LPS (1 μg/mL) for TNF-α, as positive controls 
(17-18). In order to neutralize potential effects of LPS presented in the S. mansoni recombinant 
antigens (chimera A- 2.84 EU/ml, chimera B-2.85 EU/ml), Polymyxin B (Calbiochem, Germany; 10 
μg/mL) was added to cell cultures every 12 hours during all culture period (19). The 96-well plates 
(Nunc) were maintained in an incubator at 37 oC with 5% CO2. The assays for measurement of IL-4, 
IFN-γ and TNF-α were performed using the Duoset ELISA kit (R&D Diagnostic, Minneapolis, MN) 
according to the manufacturer’s directions. 
 
2.9. Study population 
Serum was obtained from individuals living in two different endemic areas for schistosomiasis 
(“Melquiades” and “Côrrego do Onça”, Minas Gerais, Brazil). These individuals were classified in five 
groups, regarding their infection status and the selection of subjects was performed based only on 
the criteria for inclusion and exclusion of each group independent of previous knowledge of immune 
responses for each individual. Non-infected (NI) individuals, natural resistant (NR), infected (INF), 
resistant (RR) and susceptible (SR) to S. mansoni reinfection as described in Table 1. Individuals 
classified as susceptible to S. mansoni reinfection (SR) showed stool-positive examination following 
treatment (praziquantel, 40 mg/kg). The sera from RR and SR groups were obtained six months after 
praziquantel treatment and these individuals were examined for S. mansoni infection using the 
Kato–Katz technique before treatment and one, six and 12 months after treatment to check for 
reinfection rates. The water contact exposure was objectively evaluated by observers and NR, SR 
and RR groups had at least one contact daily. These individuals were followed for 24 months. 
Additionally, RR, SR and INF patients were negative for other helminthic infections. These patients or 
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their legal guardians gave informed consent after explanation of the protocol that had been 
previously approved by the Ethical Committee of the Federal University of Minas Gerais.  
 
2.10. Measurement of human humoral responses of patients living in endemic areas for 
schistosomiasis  
Sera of schistosomiasis patients living in endemic and non-endemic areas in Brazil were used in an 
ELISA (20) to measure the levels of total IgG to chimera A or chimera B. The studied population was 
divided into NI, SR, NR, RR and INF subjects (Table 1). Levels of total IgG to Sm29, chimera A and 
chimera B antigens were assessed using 96 well flat-bottom microtiter plates (Nunc) that were 
coated overnight at 4°C with 100 µl of each recombinant protein at a concentration of 5 µg/ml in 0.1 
M carbonate bicarbonate buffer (pH 9·6) per well. The plates were then blocked with 10% bovine 
fetal serum in PBS (pH 7·4) for 2 h at room temperature. Subsequently, the plates were washed 
three times with PBS plus 0.05% Tween-20 (PBST). For total IgG, serum samples were diluted 1:50 in 
PBST (100 µl/well added in duplicate) and the plates incubated for 1 h at room temperature. 
Peroxidase-labeled anti-human IgG (Sigma, St Louis, MO) was added at dilutions of 1:10000 (100 
µl/well). After 1 h at 37°C, the plates were washed and orthophenyl-diaminobenzidine plus 0.05% 
hydrogen peroxide in phosphate citrate buffer (pH 5) was added (100 µl/well). The plates were then 
incubated for 30 min at room temperature, and the reaction was stopped by addition of 5% H2SO4 
(50 µl/well). Absorbance was read at 492 nm using a microplate reader (Bio-Rad, Hercules. CA, USA). 
 
2.11. Histopathological analysis 
Following vascular perfusion of mice for recovery of the schistosomes, liver sections from mice 
(8/group) of control and experimental groups were collected to evaluate the effect of immunization 
on granuloma formation. The livers sections removed from the central part of the left lateral lobe 
were fixed with 10% buffered formaldehyde in PBS. Histological sections of 5 μm thickness were cut 
using a microtome and stained with picrosirius. Briefly, tissue slides were deparaffinized, hydrated, 
stained with 0.1% solution of Sirius Red in saturated aqueous picric acid, washed in 0.01 N HCl and 
counterstained with Harris’ Haematoxylin as previously described (21). The area from each liver 
section (mm2) was calculated using the KS300 software connected to a Carl Zeiss image analyzer. For 
measurements of the total area of granulomas, 20 granulomas with a single well-defined egg from 
each animal of a group of eight mice were randomly selected and assessed using a microscope with 
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10× objective lens. Granuloma images were obtained through a JVC TK-1270/RBG microcamera. 
Using a digital pad in the KS300 software built in a Carl Zeiss image analyzer, the areas were 
measured and expressed in square micrometers (μm2). 
 
2.12. Statistical analysis 
Statistical analysis was performed with Student’s t-test using the software package GraphPad Prism 
(La Jolla, CA, USA). Kruskal-Wallis test was used to compare the levels of IgG induced by the different 
patient groups. 
 
3. Results 
3.1.Production of recombinant chimera A and B 
Chimeras A and B were expressed as inclusion bodies and purified under denaturing conditions in 8 
M urea by nickel-affinity chromatography. The procedure for protein refolding resulted in a 
substantial loss of protein via precipitation, but yielded sufficient soluble protein to be used for 
immunization experiments. The expression and purity of chimeras A and B as 6xHis-tag fusion 
proteins were assessed by SDS-PAGE and Western blotting analysis, revealing  proteins of 
approximately 18 and 20 kDa for chimeras A and B, respectively (Figure 1), and corresponding to 
their predicted molecular weights. 
 
3.2.Antibody profile following mice immunization 
In order to evaluate the profile of the humoral immune response, total IgG and the subclasses IgG1 
and IgG2a to Sm29, chimera A and B, were measured from sera of ten vaccinated and control 
animals. All vaccinated mice developed significant levels of specific IgG, IgG1 and IgG2a antibodies 
after the second immunization compared to the non-vaccinated control group and these levels 
increased significantly after the third immunization for all tested antigens. Mice immunized with 
chimera B (SmTSP-2 fused to Sm29 C-terminus) showed significantly higher titers of IgG and IgG2a 
isotypes compared to Sm29 or chimera A antigens (Figure 2).  
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3.3. Cytokine profile 
To evaluate the cytokine profile generated by the immunization of mice with chimera A and chimera 
B, splenocytes were isolated from vaccinated and control animals after the third immunization. 
Statistically significant levels of IFN-γ and TNF-α were detected in splenocyte culture supernatants of 
chimera A and chimera B vaccinated mice compared to the control group (Figure 3). Chimera A 
immunization induced higher production of IFN-γ (712.7 ± 261.4 pg/ml) and TNF-α (407 ± 94.3 
pg/ml) compared to  chimera B immunized group (IFN-γ 328.8 ± 113.7 pg/ml; TNF-α 259 ± 38.9 
pg/ml). Additionally, no significant amounts of IL-4, a signature of Th2-immune responses, were 
detected. These results show that immunization with chimeras A and B induces a Th1 type of 
immune response in mouse T cells, characterized by the production of IFN-γ and TNF-α cytokines. 
The results of splenocyte stimulation with the positive controls ConA and LPS are not shown but 
induced high levels of these cytokines as expected. 
 
3.4. Worm burden recovery 
Protective immunity induced by vaccination with recombinant Sm29, and chimeras A and B were 
evaluated 45 days after challenge with 100 S. mansoni cercariae. Mice vaccinated with recombinant 
Sm29 (20.36%), chimera A (27.84%) and B (34.83%) showed statistically significant reduction in 
worm burden recovery compared to control mice (Table 2).  
 
3.5. Immunization with chimeras A or B induces reduction in liver pathology 
Histological analysis by digital morphometry of picrosirius-stained sections obtained from mice 
immunized with recombinant Sm29, chimera A or chimera B showed reductions of 38%, 48% and 
31% on granuloma area, respectively. These findings demonstrated that all antigens tested are 
important molecules involved in reduction of liver pathology (Figure 4).  
 
3.6. Human IgG responses to chimera A and B  
To investigate the presence of specific anti-Sm29, anti-chimera A or anti-chimera B antibodies in sera 
of individuals living in schistosomiasis endemic area ELISA was performed. Total IgG levels in sera of 
schistosomiasis patients and non-infected individuals were evaluated. The NR, INF and RR groups 
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studied had higher levels of IgG anti-chimera A or anti-chimera B compared to the non-infected 
group (Figure 5). In order to determine whether IgG responses to chimera A or chimera B could 
differentiate resistant versus susceptible individuals, we compared the NR group to INF individuals, 
and RR patients compared to the SR group. The RR patient group produced elevated levels of IgG to 
all antigens tested in this study when compared to the SR patient group. In contrast, the NR group 
did not show statistically significant higher levels of IgG to chimeras A or B when compared with the 
INF group. However, the level of specific anti-Sm29 IgG was significantly higher in the NR group 
when compared to INF subjects. Additionally, the RR group showed higher IgG levels against 
chimeras A and chimera B when compared to Sm29.  These results demonstrate that the fusion 
proteins are better recognized by human total IgG of patients with resistant phenotype compared to 
Sm29 alone. 
 
4. Discussion 
Schistosomiasis is a chronic debilitating parasitic disease that represents a major health problem in 
endemic areas, such as various parts of South America, Africa, and Southeast Asia (22). Currently, 
chemotherapy is the major control strategy used, however, extension of endemic areas and 
constant reinfection of individuals, together with poor sanitary conditions in tropical countries 
makes drug treatment inefficient (23-24). Therefore, complementary control measures, including 
vaccines could contribute enormously to disease control (25-27). Tegument proteins are of great 
importance to schistosome vaccine development since they are a major host–parasite interface (28-
29). Recently, many tegument proteins were identified and characterized including the recombinant 
proteins SmTSP-2 and Sm29. Previously, it was demonstrated that the large extracellular loop of the 
S. mansoni tegument tetraspanin, SmTSP-2, formulated with Freund's adjuvant, is an efficacious 
vaccine antigen, eliciting high levels of protection in a murine schistosomiasis model of infection (9, 
30). SmTSP-2 vaccine antigen is also protective, even when formulated with CpG-alum (30). Sm29 
recombinant protein fused to 6xHIS and used to vaccinate C57BL/6 formulated with Freund’s 
adjuvant showed a reduction of 51% in the number of adult worms, and induced a Th1 immune 
response in vaccinated mice (6, 10). Furthermore, a preparation containing GPI-anchored proteins, 
Sm29 plus other molecules engendered a mixed Th1/Th2 type of immune response in mice, which 
conferred partial protection against cercariae challenge and reduced pathology in the liver (31). 
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In the present study, we show that it is possible to induce protection in a murine schistosomiasis 
model of infection using the recombinant proteins SmTSP-2 and Sm29 in chimeric forms when 
formulated with CpG-alum, a human-approved adjuvant. C57BL/6 mice immunized with chimeras A 
and B in the presence of CpG-alum showed high levels of specific IgG, IgG1 and IgG2a that appeared 
after the second immunization. Regarding IgG1 and IgG2a subclasses, specific IgG1 against both 
chimeras was predominant. However, chimera B induced the highest levels of IgG and IgG2a 
compared to chimera A or Sm29 alone. Further, we confirmed by cytokine analysis the Th1-type of 
immune response induced following vaccination with both chimeras, characterized by high levels of 
IFN-γ and TNF-α and absence of IL-4. Studies using the irradiated cercariae model which induces high 
levels of protection in mice suggest that protection can be induced with a mixed Th1/Th2 response, 
a polarized Th1 response or even a polarized Th2 response (32). To determine whether chimera A 
and B conferred protection against S. mansoni infection, immunized mice were challenged with 100 
cercariae and worm burden analyzed. Immunization with chimera A and chimera B together with 
CpG-alum induced 27% and 34% of worm burden reduction, respectively. The involvement of IFN-γ 
in protective immunity to schistosomiasis is well documented in the murine model (32). In the 
irradiated cercariae vaccination model treatment with monoclonal anti-IFN-γ antibody totally 
abrogated the protective immunity achieved (33) showing the importance of high titers of IFN-γ in 
protective immunity in schitosomiasis. Several S. mansoni antigens tested by our group that had a 
tendency to induce a Th2 type of immune response failed to engender protection in the mouse 
model (17, 34). In contrast, Th1 antigens induced partial protection against infection (10, 18, 35).  
 
In this study, we show that the chimeric proteins A and B are protective, even when formulated with 
a human-approved adjuvant combination.   Previous studies have demonstrated that vaccination 
with recombinant Sm29 and SmTSP-2 formulated with Freund’s adjuvant provided reduction in 
worm burden and liver pathology (9-10). Herein, the association of SmTSP-2 fused to Sm29 vaccine, 
in a chimeric form, not only reduced parasite load but also the pathology and disease associated 
with schistosomiasis compared to control group that received PBS formulated with CpG-alum. 
However, when the results of vaccination with the two chimeric forms (A and B) were compared to 
Sm29 alone we did not detect statistically significant differences in worm burden and liver pathology 
among these groups. 
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Studies with sera from patients resident in schistosomiasis endemic areas revealed greater 
recognition of chimera B in NR, INF and RR groups tested, suggesting that the main B-cell epitopes of 
Sm29 probably reside predominantly within the C-terminal portion of the protein. IgG1 and IgG3 are 
associated with protective immune mechanisms including opsonization, cell cytotoxicity and 
activation of the classical complement pathway (36). Therefore, the recognition of antigens by IgG 
isotypes in individuals resistant to infection and reinfection is an important step in evaluation of the 
potential of these antigens as schistosome vaccine candidates. 
 
In conclusion, chimera A and chimera B immunization induced a Th1 type of immune response, 
worm burden reduction and diminished liver pathology in murine schistosomiasis compared to control 
group that received PBS with adjuvant.  Both chimeras were recognized by sera from natural resistant 
human subjects, and presented higher IgG levels in subjects resistant to reinfection compared to Sm29 
alone, reinforcing earlier studies on the role of these antigens as targets of naturally acquired 
immunity to schistosomiasis and the potential of these chimeric proteins in the development of an 
effective anti-schistosomiasis vaccine better than Sm29 formulated alone. 
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Figure Legends 
Figure 1: Expression and purification of chimeras A and B 6xHis fusion proteins. (A) Coomassie blue 
stained SDS-12% PAGE profile of the purified chimeras A and B proteins. Lanes: 1, rSm29 control 
(Accession number AF029222); 2, chimera A; 3, chimera B; molecular weight marker (kDa). (B) 
Western blot analysis of the purified recombinant protein using anti-6xHIS antibody. 
 
Figure 2: Kinetics of specific IgG (A), IgG1 (B) and IgG2a (C) antibody responses to chimera A and B, 
and Sm29 in mice immunized with each recombinant protein. Sera of ten immunized mice per group 
were collected at days 15, 30, 45, 60, 75 and 90 after the first immunization and assayed by ELISA. 
Results are presented as the mean absorbance measured at 492 nm for each group. Results 
represent the mean of two independent experiments. Statistically significant differences between 
responses to Sm29, chimera A and chimera B compared to control group are denoted by an asterisk 
and statistically significant differences of chimera B compared to Sm29 and chimera A are denoted 
by two asterisks for p<0.05.  
 
Figure 3: Cytokine profile of mice immunized with recombinant chimera A and chimera B proteins. 
One week after the last immunization, splenocytes from four mice were isolated and assayed for (A) 
IFN-γ and TNF-α and (B) IL-4 production in response to chimera A, chimera B and rSm29. The results 
are presented as mean ± S.D. for each group. A statistically significant difference of IFN-γ and TNF-α 
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produced by chimera A, chimera B or rSm29 vaccinated mice compared to negative control group is 
denoted by one asterisk and the difference between IL-4 produced by ConA stimulated cells 
compared to the other groups is denoted by two asterisks for P < 0.05. Results are representative of 
two independent biological experiments.  
 
Figure 4: Liver pathology measured in Sm29, chimera A or chimera B vaccinated mice. (A) The area 
of 20 granulomas from each animal of a group of eight mice with a single well-defined egg was 
measured. The total diameter of granulomas was measured, and the results were expressed as 
mean square micrometers (µm2). Statistically significant differences compared to control group are 
denoted by an asterisk (p< 0.05). (B) Histological analysis of hepatic tissue from vaccinated mice. 
Animals were sacrificed and their livers were washed in PBS and stored in formaldehyde until 
sectioning and staining with Picrosirius. (i) PBS control group, (ii) mice vaccinated with Sm29, (iii) 
mice vaccinated with Chimera A, (iv)  mice vaccinated with Chimera B. Images were captured 
using a 40x objective lens and are representative of two independent biological experiments. 
Bars, 50 µm. 
 
Figure 5: IgG antibody responses of schistosomiasis patients to Sm29, chimera A or chimera B.  
Analysis of human IgG in sera of Natural Resistant (NR); Infected (INF); Resistant to Reinfection (RR); 
Susceptible to Reinfection (SR) and Non-Infected individuals (NI) were performed by ELISA. Results 
are expressed as mean ± S.D. Statistically significant differences compared to the NI, INF, SR are 
denoted by a #,*,**, respectively, for p<0.05. Statistically significant differences compared to Sm29 
in the same group are denoted by & for p<0.05. 
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Table 1.  Study population. 
 
Group Infection status Description Age 
(mean ±SD) 
Sex 
(M/F) 
Infected (I)  
n=8 
Infected with S. 
mansoni 
Individuals living in an endemic area for 
schistomiasis with stool positive examinations 
 
17.1 ± 14.9 
 
5/3 
Susceptible to reinfection 
 (SR) 
 n=8 
Infected with S. 
mansoni 
Individuals living in a endemic area for 
schistosomiasis that present stool positive 
examination after praziquantel treatment 
 
22.8 ± 12.1 
 
3/5 
Resistant to reinfection 
(RR) 
 n=8 
Natural resistant     
(NR) 
 n=8       
Not infected 
 
 
Not infected 
Individuals living in a endemic area for 
schistosomiasis that although water contact, 
present stool negative 
examination after praziquantel treatment 
 
Non-infected individuals exposed to water 
contaminated with cercariae 
 
18.8 ± 9.3 
 
 
 
 
 
34 ± 11.2 
 
4/4 
 
 
3/5 
Non-infected 
 (NI)  
n=8 
Not infected Individuals living out of endemic area for 
schistosomiasis that never present this disease 
in their lives 
 
28.3 ± 4.5 
 
2/6 
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Table 2: Protection level induced in C57BL⁄6 mice by immunization with recombinant Sm29, chimera 
A or chimera B  
Groups Worm burden (mean±SD) Protection 
PBS + CpG-Alum 46.25 ± 3.11 -
Sm29 + CpG-Alum 36.83 ± 5.81 20.36 % * 
Chimera A + CpG-Alum 33.37 ± 5.63 27.84 % * 
Chimera B + CpG-Alum 30.14 ± 6.57 34.83 % * 
Statistical analysis were performed using Student’s t-test. *statistically significant (p <0.05) 
compared to control group. Data are representative of two independent vaccine trials. 
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